SecBot SecBot
SECBOTREPLAY Home › Report › MRK

MRK · Halozyme patent invalidated

Merck & Co., Inc. · PTAB-TRIAL filed Nov 8, 2026 at 19:00 ET

At the news

NEUTRALIMPACT 2/10

PTAB-TRIAL filed Nov 8, 2026 at 19:00 ET

In a final written decision, the PTAB held all challenged claims (1, 2, 5, and 7–33) of Halozyme's PH20 hyaluronidase patent unpatentable on written description, enablement, and obviousness grounds. Merck Sharp & Dohme LLC, the petitioner, succeeded in invalidating the patent, which is part of a broader patent dispute between Halozyme and Merck.

  • PTAB issued a final written decision in PGR2025-00042, finding claims 1, 2, 5, and 7–33 of U.S. Patent 12,037,618 unpatentable.
  • The patent covers modified PH20 hyaluronidase polypeptides with increased stability and/or activity.
  • Merck Sharp & Dohme LLC (a subsidiary of Merck & Co.) was the petitioner; Halozyme, Inc. was the patent owner.
  • The decision is based on lack of written description, lack of enablement, and obviousness over the '429 patent and Chao prior art.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access